Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557708 · ClinicalTrials.gov registry record · Early Phase 1
A Safety Study of 212Pb-Pentixather Radioligand Therapy
A Early Phase 1 study, sponsored by Yusuf Menda.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT05557708 is a Early Phase 1 study that has not yet begun recruiting, run by Yusuf Menda. The registered enrollment target is 20 participants.
The verdict
NCT05557708, a Early Phase 1 study, has not yet begun recruiting, sponsored by Yusuf Menda.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.
Interventions
- DRUG 212-Lead Pentixather
- DIAGNOSTIC_TEST 203-Lead Pentixather SPECT/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05557708
The ClinicalTrials.gov registry entry for NCT05557708 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yusuf Menda, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 212-Lead Pentixather is the first listed.
NCT05557708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05557708 about?
NCT05557708 is a clinical study titled "A Safety Study of 212Pb-Pentixather Radioligand Therapy". This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.
What is the current status of trial NCT05557708?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-07-01. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT05557708?
The interventions under investigation include: 212-Lead Pentixather (DRUG), 203-Lead Pentixather SPECT/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05557708?
This trial is sponsored by Yusuf Menda, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.